Literature DB >> 6704779

Dantrolene--in vitro studies in malignant hyperthermia susceptible (MHS) and normal skeletal muscle.

B A Britt, E Scott, W Frodis, M J Clements, L Endrenyi.   

Abstract

Dantrolene sodium, a hydantoin analogue, is efficacious in the therapy of malignant hyperthermia (MH). In order to improve our knowledge of the mode of action of dantrolene, we have examined the influence of dantrolene sodium on: (1) twitch and resting tensions, in the absence and the presence of caffeine, of intact skeletal muscle fascicles; and (2) caffeine induced tension rises of single chemically skinned skeletal muscle fascicles. We have found that dantrolene appears to exert its beneficial action on malignant hyperthermia susceptible (MHS) skeletal muscle by an indirect action on the sarcoplasmic reticulum (SR). Thus dantrolene inhibits twitch tensions of skeletal muscle fascicles, probably by indirectly preventing the release of calcium from the SR. To a lesser extent dantrolene inhibits caffeine induced contractures of skeletal muscle fascicles, probably by indirectly accelerating the uptake of calcium into the SR. Because the former effect is greater than the latter in vivo dantrolene sodium is effective only when given prior to total loss of calcium from the SR. Vigilant temperature and EKG monitoring of all patients during anaesthesia is, therefore, essential.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6704779     DOI: 10.1007/bf03015252

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


  48 in total

1.  Dantrolene and A13187 ionophore: specific action on calcium channels revealed by the aequorin method.

Authors:  J E Desmedt; K Hainaut
Journal:  Biochem Pharmacol       Date:  1979-04-01       Impact factor: 5.858

2.  The effects of pentobarbital on 2,4-dinitrophenol induced malignant hyperthermia during halothane general anesthesia in dogs.

Authors:  M J Hull; W W Webster; E Gatz
Journal:  J Oral Surg       Date:  1971-09

3.  [Therapy of neuroleptic malignant syndrome with dantrolene].

Authors:  J L Delacour; P Daoudal; J L Chapoutot; B Rocq
Journal:  Nouv Presse Med       Date:  1981-11-28

Review 4.  Dantrolene.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1984-01

5.  Effects of dantrolene sodium on the excitation-contraction coupling of the mammalian and amphibian cardiac muscle.

Authors:  J Hatae; M Ohba; H Kawata
Journal:  J Mol Cell Cardiol       Date:  1980-09       Impact factor: 5.000

6.  Recrudescence after survival of an initial episode of malignant hyperthermia.

Authors:  A Mathieu; A J Bogosian; J F Ryan; R K Crone; D Crocker
Journal:  Anesthesiology       Date:  1979-11       Impact factor: 7.892

7.  A comparison of the effects of sodium thiocyanate and dantrolene sodium on a mammalian isolated skeletal muscle.

Authors:  R F Moulds
Journal:  Br J Pharmacol       Date:  1977-01       Impact factor: 8.739

8.  Rationale for dantrolene vs. procainamide for treatment of malignant hyperthermia.

Authors:  T E Nelson; E H Flewellen
Journal:  Anesthesiology       Date:  1979-02       Impact factor: 7.892

9.  Inhibition of the intracellular release of calcium by Dantrolene in barnacle giant muscle fibres.

Authors:  J E Desmedt; K Hainaut
Journal:  J Physiol       Date:  1977-02       Impact factor: 5.182

10.  Comparison of the caffeine skinned fibre tension (CSFT) test with the caffeine-halothane contracture (CHC) test in the diagnosis of malignant hyperthermia.

Authors:  B A Britt; W Frodis; E Scott; M J Clements; L Endrenyi
Journal:  Can Anaesth Soc J       Date:  1982-11
View more
  5 in total

Review 1.  Etiopathogenetic defect of malignant hyperthermia: hypersensitive calcium-release channel of skeletal muscle sarcoplasmic reticulum.

Authors:  P J O'Brien
Journal:  Vet Res Commun       Date:  1987       Impact factor: 2.459

Review 2.  Malignant hyperthermia susceptibility: biochemical basis for pathogenesis and diagnosis.

Authors:  P J O'Brien; A Klip; B A Britt; B I Kalow
Journal:  Can J Vet Res       Date:  1990-01       Impact factor: 1.310

Review 3.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

4.  Malignant hyperthermia in an office surgery suite: a case report.

Authors:  I M Turpin; J Manino
Journal:  Aesthetic Plast Surg       Date:  1989       Impact factor: 2.326

5.  Diltiazem and nifedipine reduce the in vitro contracture response to halothane in malignant hyperthermia-susceptible muscle.

Authors:  P J Adnet; R M Krivosic-Horber; G Haudecoeur; H G Reyford; M M Adamantidis; B A Dupuis
Journal:  Can J Anaesth       Date:  1990-07       Impact factor: 5.063

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.